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Background: The Japanese Registry of NeuroEndovascular Therapy 2 (JR-NET2) and 3 
(JR-NET3) were nationwide surveys that evaluated clinical outcomes after neuroendovascular 
therapy in Japan. The aim of this study was to compare the prevalence and risk factors of 
complications of intracranial tumor embolization between JR-NET2 and JR-NET3. 
Methods: A total of 1018 and 1545 consecutive patients with intracranial tumors treated with 
embolization were enrolled in JR-NET2 and JR-NET3, respectively. The prevalence of 
complications in intracranial tumor embolization and related risk factors were compared 
between JR-NET2 and JR-NET3. 
Results: The prevalence of complications in JR-NET3 (3.69%) was significantly higher than 
that in JR-NET2 (1.48%) (p = 0.002). The multivariate analysis in JR-NET2 showed that 
embolization for tumors other than meningioma was the only significant risk factor for 
complication (odds ratio [OR], 3.88; 95% confidence interval [CI], 1.13-12.10; p = 0.032), 
and that in JR-NET3 revealed that embolization for feeders other than external carotid artery 
(ECA) (OR, 3.56; 95% CI, 2.03-6.25; p < 0.001) and use of liquid materials (OR, 2.65; 95% 
CI, 1.50-4.68; p < 0.001) were significant risks for complications. The frequency of 
embolization for feeders other than ECA in JR-NET3 (15.3%) was significantly higher than 
that in JR-NET2 (9.2%) (p < 0.001). Also, there was a significant difference in the frequency 





Conclusions: Embolization for feeders other than ECA and use of liquid materials could 
increase the complication rate in intracranial tumor embolization. 
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Embolization for intracranial tumors before surgical resection, especially for extra-axial 
hypervascular tumors, is routine in the clinical setting in Japan. The aims of preoperative 
embolization are to remove devascularized tumors safely, to shorten the operation time, and to 
avoid blood loss and transfusion. The multicenter Japanese Registry of NeuroEndovascular 
Therapy (JR-NET) Study Group was formed in 2005 to determine annual trends, including 
adverse events and clinical outcomes 30 days after neuroendovascular therapy [17]. JR-NET1 
ran from January 2005 to December 2006, JR-NET 2 from January 2007 to December 2009, 
and JR-NET3 from January 2010 to December 2014. JR-NET1, JR-NET2, and JR-NET3 
consisted of the following kinds of treatment modalities: embolization for cerebral aneurysms, 
cerebral arteriovenous malformations (AVM), spinal vascular lesions, intracranial dural 
arteriovenous fistulas; intracranial tumor embolization; carotid artery stenting; 
intra/extracranial artery percutaneous transluminal angioplasty or stenting; recanalization for 
acute major artery occlusion and remission for cerebral vasospasm after aneurysmal 
subarachnoid hemorrhage [2-9,11,14,18,20,22]. The results of embolization of meningiomas 
and other intracranial tumors were evaluated in JR-NET2 and JR-NET3 and reported, 
respectively [6,21]. The aims of this study were to compare the prevalence and risk factors of 
complications of intracranial tumor embolization between JR-NET2 and JR-NET3 and to 






Patients and Methods 
A total of 1018 and 1545 consecutive patients with intracranial tumors treated with 
embolization were enrolled in JR-NET2 and JR-NET3, respectively [6,21]. The primary end 
point was the proportion of patients with a modified Rankin scale (mRS) score of 0-2 at 30 
days after the procedure, and the secondary end point was the occurrence of complications 
related to the procedures in both studies. The study protocols of JR-NET2 and JR-NET3 were 
approved by the institutional review board at Kobe City Medical Center General Hospital. 
Because this was a retrospective noninvasive study, written informed consent was not 
obtained from patients. 
As was the case with JR-NET2 [6], age, gender, preoperative mRS, type of tumor, 
anesthesia, scheduled intervention, main operator, target vessels, and results of embolization 
were checked as baseline characteristics for 1545 patients in JR-NET3. The Japanese Society 
of Neuro-Endovascular Therapy has a Specialist Qualification System through which it 
certifies two classes of specialists: specialists and consulting specialists. A consulting 
specialist is a senior specialist who must already be qualified as a specialist. In JR-NET2 and 
JR-NET3, a specialist or consulting specialist had to participate in each patient’s 
neuroendovascular treatment. OnyxTM (Medtronic, Minneapolis, Minnesota) was newly added 





categorized as the feeders from the external carotid artery (ECA) and those from other than 
ECA, such as internal carotid or vertebrobasilar artery. The results of embolization was 
graded as total, subtotal, partial and unchanged. 
Procedural complications were defined as any neurological deficit or death that 
occurred during or after embolization. Abnormalities after embolization, such as intracranial 
ischemic or hemorrhagic changes on computed tomography or magnetic resonance imaging 
were also classified as procedural complications even if the patients were asymptomatic. 
Statistical analysis 
Quantitative variables are presented as a percentage or as the median and interquartile ranges. 
Statistical analysis was performed using Fisher’s exact probability test, the chi-square test, 
and the Mann-Whitney U test, as appropriate. All statistical analyses were performed using 
EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical 
user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [10]. When 
variables associated with the occurrence of complications had a probability value less than 
0.05 using a univariate analysis, they were selected for a multivariate analysis. Differences 
were considered to be significant when p values were less than 0.05. 
 
Results 





information for evaluation, 1012 (637 females, median age 60 years  [interquartile range 
(IQR) 50-68 years]) and 1544 patients (937 females, median age 63 years [IQR 52-70 years]) 
were analyzed in JR-NET2 and JR-NET3, respectively. 
 Table 1 shows the patient characteristics in JR-NET2 and JR-NET3. Table 2 presents 
a comparison of patient characteristics and incidence of end points between JR-NET2 and 
JR-NET3. The primary end point (mRS score ≤ 2 at 30 days after the procedure) was 
observed in 924 patients (91.3%) and 1382 patients (89.5%), respectively. Fifteen of the 1012 
patients (1.48%) suffered from procedural complications in JR-NET2, and 57 of the 1544 
patients (3.69%) in JR-NET3. The prevalence of complications in JR-NET3 was significantly 
higher than that in JR-NET2 (p = 0.002). 
Types and outcomes of complications 
Table 3 presents the types and outcomes of complications related to the embolization 
procedures in both studies. The types of complications consisted of intracranial hemorrhage, 
ischemia, and others. There were no significant differences in the types of complications 
between JR-NET2 and JR-NET3 (p = 0.33). The outcomes of complications were classified as 
minor and major; minor complications included no symptoms or transient symptoms with 
complete remission within 30 days, and major complications included a more than 1 point 
decrease in mRS score. The prevalence of major complications in JR-NET3 tended to be 





4 reveals the association between the types and outcomes of complications in JR-NET2 and 
JR-NET3. The hemorrhagic complication was significantly associated with major outcome in 
JR-NET2 (p = 0.042), and the ischemic complication was significantly correlated with major 
outcome in JR-NET3 (p = 0.034). 
Risk factors of complications 
Table 5 shows the results of univariate and multivariate analysis for risk factors related to the 
complications in JR-NET2 and JR-NET3. The multivariate analysis in JR-NET2 showed that 
embolization for tumors other than meningioma was the only significant risk factor for 
complication (OR, 3.88; 95% CI, 1.13-12.10; p = 0.032), and that in JR-NET3 revealed that 
embolization for feeders other than ECA (OR, 3.56; 95% CI, 2.03-6.25; p < 0.001) and use of 
liquid materials (OR, 2.65; 95% CI, 1.50-4.68; p < 0.001) were significant risks of 
complications. 
Comparison of the types and outcomes of complications between with and without 
embolization for feeders other than ECA and use of liquid materials in JR-NET3 
Table 6 demonstrates the comparison of the types and outcomes of complications between 
with and without embolization for feeders other than ECA and use of liquid materials in 
JR-NET3. The prevalence of ischemic complications with embolization for feeders other than 
ECA was significantly higher than that without embolization for feeders other than ECA 





were significantly poorer than those without use of liquid materials (p = 0.03). 
 
Discussion 
The JR-NET series were nationwide surveys and representative of large-scale studies related 
to the results of neuroendovascular therapies in Japan. In terms of intracranial tumor 
embolization, JR-NET2 and JR-NET3 were unprecedented large cohort studies, and this is the 
first report to compare the prevalence and risks of complications in intracranial tumor 
embolization between the largest cohorts in the same nation. The important findings in this 
investigation are as follows: first, the prevalence of complications in JR-NET3 was 
approximately 2.5 times higher than that in JR-NET2, and the difference was significant (p = 
0.002); second, the significant risk factors of complications were different between JR-NET2 
and JR-NET3, namely embolization for tumors other than meningioma in JR-NET2 and 
embolization for feeders other than ECA and use of liquid materials in JR-NET3, respectively. 
The increase in the prevalence of complications in JR-NET3 is likely attributable to 
embolization for feeders other than ECA and use of liquid materials, according to multivariate 
analysis for risk factors of complications. 
The occurrence of ischemic complication in the central nervous system is of concern 
in patients with embolization for feeders other than ECA [15]. Our data revealed that the 





approximately 1.5 times higher than that in JR-NET2 (9.2%) and the difference was 
significant (Table 2). Also, in JR-NET3, the prevalence of ischemic complications in patients 
with embolization for feeders other than ECA was significantly higher than that in patients 
with embolization for ECA feeders (Table 5). The complication rate of intracranial meningeal 
tumor embolization for feeders other than ECA was reported to be 9% [15]. Rosen et al. 
analyzed the results of embolization for 167 skull base meningiomas, in which 41% were 
embolized for meningohypophyseal arteries from ICA and revealed that 12.6% and 9% of all 
patients experienced transient and permanent neurological deficits as a result of embolization, 
respectively [16]. Wadron et al. put forth that the high complication rate in this study was 
attributable to the goal of complete occlusion of all feeders including feeders from ICA and 
proposed that complication avoidance should be emphasized over complete devascularization 
[23]. 
N-butyl cyanoacryllate (NBCA) is the most popular liquid material used in 
intracranial tumor embolization in Japan. The rapid penetration into tumor vasculature and the 
permanent effect of embolization are advantages of NBCA in embolization, but its use has 
several risks, such as penetration into the pial vessels through the intratumoral anastomosis 
and the reflux into normal vessels due to target vessel occlusion [12,13]. Furthermore, in 
contrast to particle embolizaton, technical skill and experience are required during NBCA 





patients with intracranial meningiomas preoperatively embolized using NBCA, and the 
complications included arterio-venous fistulas, NBCA migration, and aggravation of brain 
edema or tumor swelling [1]. In JR-NET3, use of liquid materials was a significant risk for 
complication and was significantly related to the degree of complication severity (Table 5). 
The frequency of use of liquid materials in JR-NET3 (41.2%) was significantly higher 
(approximately 2 times) than that in JR-NET2 (21.2%) (Table 2) and its frequency in 
JR-NET3 was very high compared to other reports [15,19]. Several reasons for the high 
frequency of the use of liquid materials in JR-NET3 can be considered. First, some 
investigations have reported the efficacy of liquid materials in intracranial tumor embolization 
[13,24]. Second, OnyxTM was introduced to the Japanese neurosurgical field as a treatment 
covered by Japanese public health insurance system for cerebral AVM in 2008. Subsequently, 
Japanese endovascular surgeons became aware that they should be familiar with the handling 
of liquid materials, and this likely increased the use of liquid materials in tumor embolization. 
Embolization for feeders other than ECA or the use of liquid materials, so-called aggressive 
embolization, should be considered carefully from the risk-benefit viewpoint in intracranial 
tumor embolization. 
There are several limitations in both JR-NET2 and JR-NET3. First, these studies are 
retrospective in nature with little in the way of details regarding the size and location of the 





occurrence of complications. Also, because information on operation time and volume of 
blood loss is not included in these studies, the benefits of intracranial tumor embolization 
before resection could not be clarified. Second, there is a case-selection bias in these studies. 
Meningiomas are more likely to be targets of preoperative embolization because of the 
technical ease and the indication of embolization for tumors other than meningioma is largely 
at the physician’s discretion. Although this type of bias could prevent the accurate assessment 
of risk factors of complications in intracranial tumor embolization, they are thought to be 
unavoidable in observational studies like JR-NET2 and JR-NET3. 
 
Conclusions 
The prevalence of complications in JR-NET3 was approximately 2.5 times higher than that in 
JR-NET2. This increase is likely attributable to embolization for feeders other than ECA and 
the use of liquid materials. These aggressive embolizations should be considered carefully in 
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Age, yr (median, IQR) 60 (50-68) 63 (52-70) 
Female sex 637 (62.9) 937 (60.7) 
Preoperative mRS   
 0 696 (68.8) 1034 (67.0) 
 1 173 (17.1) 271 (17.5) 
 2 77 (7.6) 137 (8.9) 
 3 26 (2.6) 58 (3.7) 
 4 25 (2.4) 34 (2.2) 
 5 3 (0.3) 6 (0.4) 
 Data not acquired 12 (1.2) 4 (0.3) 
Type of tumors   
 Meningioma 898 (88.7) 1337 (86.6) 
 Hemangioblastoma 25 (2.5) 72 (4.7) 
 Glioma 6 (0.6) 10 (0.6) 
 Others 78 (7.7) 121 (7.8) 
 Data not acquired 5 (0.5) 4 (0.3) 
Anesthesia   
 General 42 (4.2) 203 (13.1) 
 Local 968 (94.4) 1338 (86.7) 
 Data not acquired 2 (0.2) 3 (0.2) 
Scheduled intervention   
 Yes 966 (98.4) 1520 (98.4) 
 No 16 (1.6) 21 (1.4) 
 Data not acquired 0 3 (0.2) 
Main operator   
 Consulting specialist 427 (42.2) 648 (42.0) 
 Specialist 460 (45.4) 772 (50.0) 
 Non-specialist 125 (12.3) 122 (7.9) 
 Data not acquired 0 2 (0.1) 
Target vessels   
 ECA only 908 (89.7) 1294 (83.8) 
 Other than ECA 92 (9.1) 233 (15.1) 
 Data not acquired 12 (1.2) 17 (1.1) 





 Coil 607 (60.0) 827 (53.6) 
 Particle 596 (58.9) 632 (40.9) 
 Liquid 214 (21.1) 627 (40.6) 
 Data not acquired 2 (0.2) 23 (1.5) 
Results of embolization   
 Total 344 (34.0) 385 (24.9) 
 Subtotal 414 (40.9) 627 (40.6) 
 Partial 238 (23.5) 492 (31.9) 
 Unchanged 7 (0.7) 16 (1.0) 
 Data not acquired 9 (0.9) 24 (1.6) 
 
Age is presented as the median and interquartile range (IQR); other values are presented as 
the raw numbers with percentages in parentheses. 





Table 2 Comparison of patient characteristics and incidence of end points between JR-NET2 
and JR-NET3 
 
 JR-NET2 JR-NET3 p value 
Age, yr (median, IQR) 60 (50-68) 63 (52-70) <0.001 
Female sex 637 (62.9) 937 (60.7) 0.27 
Preoperative mRS   0.36 
 0-2 946 (94.6) 1442 (93.6)  
 3-5 54 (5.4) 98 (6.4)  
Type of tumors    
 Meningioma 898 (89.2) 1337 (86.8) 0.09 
 Other than meningioma 109 (10.8) 203 (13.2)  
Anesthesia   <0.001 
 General 42 (4.2) 203 (13.2)  
 Local 968 (95.8) 1338 (86.8)  
Scheduled intervention   0.71 
 Yes 966 (98.4) 1520 (98.6)  
 No 16 (1.6) 21 (1.4)  
Main operator    
 Non-specialist 125 (12.4) 122 (7.9) <0.001 
 Other than non-specialist 887 (87.6) 1420 (92.1)  
Target vessels   <0.001 
 ECA only 908 (90.8) 1294 (84.7)  
 Other than ECA 92 (9.2) 233 (15.3)  
Embolic materials    
 Coil 607 (60.1) 827 (54.4) 0.005 
 Other than coil 403 (39.9) 694 (45.6)  
 Particle 596 (59.0) 632 (41.6) <0.001 
 Other than particle 414 (41.0) 889 (58.4)  
 Liquid 214 (21.2) 627 (41.2) <0.001 
 Other than liquid 796 (78.8) 894 (58.8)  
Results of embolization    
 Total 344 (34.3) 385 (25.3) <0.001 
 Other than total 659 (65.7) 1135 (74.7)  
End points    
mRS score ≤ 2 at 30 days 
after procedure (primary 
end point) 






(secondary end point) 
15 (1.48) 57 (3.69) 0.002  
 
Age is presented as the median and interquartile range (IQR); other values are presented as 
the raw numbers with percentages in parentheses. 












Types of complications   0.33 
 Hemorrhage 4 (26.7) 7 (12.3)  
 Ischemia 6 (40.0) 32 (56.1)  
 Others 5 (33.3) 18 (31.6)  
Outcomes of 
complications 
  0.30 
 Minor 13 (86.7) 38 (66.7)  
 Major 2 (13.3) 17 (29.8)  
 Data not acquired 0 2 (3.5)  
 










p value JR-NET3 
(n=57) 
p value 
 Outcomes of 
complications 
 Outcomes of 
complications 
 
 Minor Major  Minor Major  
Types of 
complications 
      
 Hemorrhage 2 (15.4) 2 (100)  6 (15.8) 1 (5.9)  
 Ischemia 6 (46.1) 0 (0) 0.042 17 (44.7) 14 (82.3) 0.034 
 Others 5 (38.5) 0 (0)  15 (39.5) 2 (11.8)  
 








Table 5 Univariate and multivariate analysis: Risk factors related to the development of 
complication in JR-NET2 and JR-NET3 
 
 JR-NET2 JR-NET3 
 Univariate analysis   Multivariate analysis Univariate analysis Multivariate analysis 
Risk factors Occurrence of 
complications 






p value Hazard ratio 
(95% CI) 
p value 
Yes No Yes No 











0.27   
Female sex 13 (87) 623 (63) 0.062   26 (46) 911 (61) 0.025 0.64 
(0.37-1.09) 
0.1 
mRS 3-5 3 (20) 51 (5) 0.043 4.54 
(0.96-16.01) 
0.055 7 (12) 91 (6) 0.11   
Other than 
meningioma 
6 (40) 103 (10) 0.0003 3.88 
(1.13-12.10) 
0.032 12 (21) 191 (13) 0.097   
General 
anesthesia 
2 (13) 40 (4) 0.13   11 (19) 192 (13) 0.23   
Scheduled 
procedure 
14 (93) 981 (98) 0.21   55 (98) 1465 (99) 1   
Non-specialist 2 (15) 123 (12) 0.71   4 (7) 118 (8) 1   
Other than 
ECA 
4 (27) 93 (9) 0.049 1.98 
(0.46-6.97) 
0.34 23 (40) 210 (14) <0.001 3.56 
(2.03-6.25) 
<0.001 
Coil 9 (60) 598 (60) 0.99   22 (39) 805 (55) 0.021   
Liquid 
materials 
7 (47) 206 (21) 0.015 2.70 
(0.87-8.03) 





5 (33) 591 (59) 0.061   13 (23) 619 (42) 0.005   
Total 
embolization 
3 (20) 341 (34) 0.29   9 (16) 376 (26) 0.13   
 
Age is presented as the median and interquartile range (IQR); other values are presented as 
the raw numbers with percentages in parentheses. 





Table 6 Comparison of the types and outcomes of complications between with and without 
embolization for feeders other than ECA and the use of liquid materials in JR-NET3 
 
 Embolization for 
feeders other than 
ECA 
p value Use of liquid 
materials 
p value 
 Yes No  Yes No  
Types of 
complications 
  <0.001   0.29 
 Hemorrhage 4 (17.4) 3 (8.8)  4 (10.5) 3 (15.8)  
 Ischemia 18 (78.2) 14 (41.2)  24 (60.2) 8 (42.1)  
 Others 1 (4.4) 17 (50.0)  10 (29.3) 8 (42.1)  
Outcomes of 
complications 
  1   0.03 
 Minor 16 (69.6) 22 (68.8)  22 (57.9) 15 (88.2)  
 Major 7 (30.4) 10 (31.2)  16 (42.1) 2 (11.8)  
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